Kardiale MRT bei nichtischämischen Kardiomyopathien

[1]  H. Origasa,et al.  Thromboembolic events in left ventricular non-compaction: comparison between children and adults – a systematic review and meta-analysis , 2022, Open Heart.

[2]  Husam M. Salah,et al.  COVID-19 Vaccine and Myocarditis , 2021, The American Journal of Cardiology.

[3]  S. Heymans,et al.  Myocarditis and inflammatory cardiomyopathy: current evidence and future directions , 2020, Nature Reviews Cardiology.

[4]  A. Mazzanti,et al.  Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria. , 2020, International journal of cardiology.

[5]  M. Salerno,et al.  Native T1 Mapping, Extracellular Volume Mapping, and Late Gadolinium Enhancement in Cardiac Amyloidosis: A Meta-Analysis. , 2020, JACC. Cardiovascular imaging.

[6]  R. Falk,et al.  How to Image Cardiac Amyloidosis: A Practical Approach. , 2020, JACC. Cardiovascular imaging.

[7]  J. Müller-Quernheim,et al.  Sarkoidose , 2020, Der Pneumologe.

[8]  G. Pontone,et al.  Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis. , 2020, JACC. Cardiovascular imaging.

[9]  C. Lavie,et al.  Left ventricular hypertrophy and hypertension. , 2019, Progress in cardiovascular diseases.

[10]  P. Elliott,et al.  Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta‐analysis , 2019, ESC heart failure.

[11]  A. Durães,et al.  Endomyocardial fibrosis: past, present, and future , 2019, Heart Failure Reviews.

[12]  C. Lücke,et al.  Original versus 2018 Lake Louise Criteria for Acute Myocarditis Diagnosis: Old versus New. , 2019, Radiology. Cardiothoracic imaging.

[13]  P. Kyriakou,et al.  Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers , 2018, BMC Cardiovascular Disorders.

[14]  C. Antoniades,et al.  Diagnostic Accuracy of Cardiovascular Magnetic Resonance in Acute Myocarditis: A Systematic Review and Meta-Analysis. , 2018, JACC. Cardiovascular imaging.

[15]  Y. Yamashita,et al.  Base-to-apex gradient pattern of cardiac impairment identified on myocardial T1 mapping in cardiac amyloidosis , 2018, Radiology case reports.

[16]  D. Okada,et al.  Isolated cardiac sarcoidosis: A focused review of an under-recognized entity , 2018, Journal of Nuclear Cardiology.

[17]  S. Vasanawala,et al.  18F-florbetaben whole-body PET/MRI for evaluation of systemic amyloid deposition , 2018, EJNMMI Research.

[18]  K. Asai,et al.  Non-contrast-enhanced T1 Mapping of Dilated Cardiomyopathy: Comparison between Native T1 Values and Late Gadolinium Enhancement , 2018, Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine.

[19]  D. Skowasch,et al.  Kardiale Sarkoidose , 2018, Der Pneumologe.

[20]  Amit R. Patel,et al.  Role of Cardiac Magnetic Resonance in the Diagnosis and Prognosis of Nonischemic Cardiomyopathy. , 2017, JACC. Cardiovascular imaging.

[21]  E. Braunwald,et al.  Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. , 2017, Circulation research.

[22]  G. Hindricks,et al.  CMR-Derived Extracellular Volume Fraction as a Marker for Myocardial Fibrosis: The Importance of Coexisting Myocardial Inflammation. , 2017, JACC. Cardiovascular imaging.

[23]  Qiu-ying Yao,et al.  Fibrosis quantification in Hypertensive Heart Disease with LVH and Non-LVH: Findings from T1 mapping and Contrast-free Cardiac Diffusion-weighted imaging , 2017, Scientific Reports.

[24]  V. Fuster,et al.  18F-Sodium Fluoride PET/MR for the Assessment of Cardiac Amyloidosis. , 2016, Journal of the American College of Cardiology.

[25]  Yeong-Hoon Choi,et al.  Cardiac Hypertrophy: An Introduction to Molecular and Cellular Basis , 2016, Medical science monitor basic research.

[26]  S. Punwani,et al.  Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis , 2015, Journal of cardiovascular computed tomography.

[27]  B. Schnackenburg,et al.  Performance of T1 and T2 Mapping Cardiovascular Magnetic Resonance to Detect Active Myocarditis in Patients With Recent-Onset Heart Failure , 2015, Circulation. Cardiovascular imaging.

[28]  M. Emdin,et al.  Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging , 2015, Journal of internal medicine.

[29]  H. Katus,et al.  Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center study , 2015, Clinical Research in Cardiology.

[30]  J. Airaksinen,et al.  Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. , 2015, Circulation.

[31]  B. Schnackenburg,et al.  CMR in patients with severe myocarditis: diagnostic value of quantitative tissue markers including extracellular volume imaging. , 2014, JACC. Cardiovascular imaging.

[32]  C. Catalano,et al.  CMR sensitivity varies with clinical presentation and extent of cell necrosis in biopsy-proven acute myocarditis. , 2014, JACC. Cardiovascular imaging.

[33]  Tiina Heliö,et al.  Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2013, European heart journal.

[34]  M. Robson,et al.  Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. , 2013, JACC. Cardiovascular imaging.

[35]  Reza Razavi,et al.  Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. , 2013, JACC. Cardiovascular imaging.

[36]  J. Hoffmann,et al.  Value of cardiovascular MR in diagnosing left ventricular non-compaction cardiomyopathy and in discriminating between other cardiomyopathies , 2012, European Radiology.

[37]  M. Laakso,et al.  Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathy , 2012, Heart.

[38]  Michael C Iannuzzi,et al.  Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. , 2011, JAMA.

[39]  Matthias Gutberlet,et al.  Prevalence and functional impact of lipomatous metaplasia in scar tissue following myocardial infarction evaluated by MRI , 2010, European Radiology.

[40]  Wojciech Zareba,et al.  Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: Proposed Modification of the Task Force Criteria , 2010, Circulation.

[41]  C. Lücke,et al.  Inflammation in takotsubo cardiomyopathy: insights from cardiovascular magnetic resonance imaging , 2010, European Radiology.

[42]  Matthias Gutberlet,et al.  Cardiovascular Magnetic Resonance in Myocarditis: A JACC White Paper , 2009 .

[43]  Luigi Rega,et al.  Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. , 2008, Journal of the American College of Cardiology.

[44]  Eloisa Arbustini,et al.  Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2007, European heart journal.

[45]  A. Angelini,et al.  A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. , 2007, European heart journal.

[46]  Barry J Maron,et al.  Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interd , 2006, Circulation.

[47]  J. Schulz-Menger,et al.  Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. , 2005, Journal of the American College of Cardiology.

[48]  D P Schutte,et al.  Clinical profile and outcome of idiopathic restrictive cardiomyopathy. , 2001, Circulation.

[49]  O Strohm,et al.  Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. , 1998, Circulation.

[50]  B. McManus,et al.  A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. , 1995, The New England journal of medicine.

[51]  M. Yamaguchi,et al.  The frequency of sarcoidosis in Finland and Hokkaido, Japan. A comparative epidemiological study. , 1995, Sarcoidosis.

[52]  C. Kawai,et al.  Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies. , 1980, British heart journal.

[53]  T. Umeda,et al.  Hypertrophic nonobstructive cardiomyopathy with giant negative T waves (apical hypertrophy): ventriculographic and echocardiographic features in 30 patients. , 1979, The American journal of cardiology.

[54]  Spectroscopic Binaries,et al.  THE FREQUENCY OF , 2016 .

[55]  H. Schild,et al.  Diagnostic value of quantitative CMR in patients suspected of having myocarditis: a question of timing. , 2015, JACC. Cardiovascular imaging.

[56]  H. Kok,et al.  Left ventricular non-compaction cardiomyopathy. , 2012, JBR-BTR : organe de la Societe royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie.